ArticleBMC genomics2025
Dynamic transcriptome and metabolome analyses of two sweet corn lines under artificial aging treatment.
Article in BMC genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transcriptomic Profiling Reveals the Seed Aging Process inPlants (Basel, Switzerland) · 2026Article
- Integrated Transcriptomic and Metabolomic Analysis Reveals Metabolic Heterosis in Hybrid Tea Plants (Genes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundStrong tolerance to seed aging is an important agricultural trait for sweet corn production. Previous studies have primarily focused on the QTLs for the seed vigor. However, there were few researches involving in the metabolome and transcriptome of artificial aging seeds.
resultsUsing two inbred lines with significant differences in seed artificial aging tolerance, RNA sequencing and non-targeted metabolomic analysis were employed to extensively evaluate transcripts and metabolites in seeds that underwent artificial aging. Fourteen common transcripts and 16 common metabolites with sustained differential expression were identified in the two lines, suggesting their potential necessity in seed response to artificial aging. Enrichment analysis of differentially expressed genes (DEGs) in the transcriptome at different stages revealed significant enrichment KEGG pathways, "Oxidative phosphorylation" was the common pathway in the 0d vs 3d comparison for K107 and L155. The identical enriched KEGG pathways were observed in the 3d vs 6d comparison for K107 and 0d vs 6d comparison for L155, indicating a slower transcriptomic response in the aging-tolerance line. DEGs at 0 days between the two lines had been enriched in the "Terpenoid backbone biosynthesis" and "Ribosome" pathways, while at 6 days, the enrichment pathway were "Sulfur metabolism", "Linoleic acid metabolism", and "Plant hormone signal transduction". A total of 312 differentially expressed metabolites (DEMs) were found at 0, 3 and 6 days after seed aging treatment, and they shared enriched metabolic pathway of "ABC transporters". The KEGG enrichment of DEGs and DEMs shared the common pathway, namely "Linoleic acid metabolism". Among these, the most abundant metabolites were Glutathione, Adenosine, Trehalose, and 10E,12Z-Octadecadienoic acid. Focusing on the ascorbate-glutathione pathway revealed that the difference in ROS production and the ROS scavenging capability mediated by glutathione S-transferase (GST) genes were important factors contributing to the differing seed aging tolerance in the two lines.
conclusionIn summary, these results contribute to a deeper understanding of the overall mechanisms underlying artificial aging tolerance in sweet corn seeds. The findings of this study are expected to provide valuable insights for the storage of sweet corn seeds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.